BioCentury | Nov 10, 2016
Strategy

Editing the claims

...exclusive licensing option to Servier to develop and commercialize six Cellectis cancer products; and granted genOway S.A....
...NASDAQ:CLLS), Paris, France CRISPR Therapeutics AG (NASDAQ:CRSP), Basel, Switzerland Editas Medicine Inc. (NASDAQ:EDIT), Cambridge, Mass. genOway S.A....
BioCentury | Feb 10, 2014
Company News

Cellectis, genOway deal

...Cellectis granted genOway an exclusive sublicense to Cellectis' homologous recombination technology for research applications in genetically...
...to Cellectis' homologous recombination technology for research applications in genetically modified rodents. Under the deal, genOway...
...Paris, France). Cellectis has exclusive rights to the institute's technology. Cellectis S.A. (Euronext:ALCLS), Paris, France genOway S.A....
BioCentury | Mar 26, 2012
Company News

genOway, StemCells deal

...dual expression of a protein of interest and a selectable marker. Details were not disclosed. genOway S.A....
BioCentury | Jul 18, 2011
Company News

bluebird bio, genOway deal

...bluebird granted genOway exclusive, worldwide rights to its RMCE technology for use in genetically modified rodents...
...sequence at a specific locus. Terms were not disclosed. bluebird bio Inc. , Cambridge, Mass. genOway S.A....
BioCentury | Mar 21, 2011
Company News

Genfit, OSEO diagnostic news

...cardiovascular disease. Genfit will lead the consortium of the program, which includes functional genomics company genOway S.A....
BioCentury | Jun 21, 2010
Company News

genOway deal

...to develop genetically modified animal models for testing pharmaceutical compounds. Further details were not disclosed. genOway S.A....
BioCentury | May 24, 2010
Company News

genOway, Griffith University deal

...to establish germline transmission in rats. Both partners are responsible for their respective R&D costs. genOway...
...receive an exclusive, worldwide license to use the technology to create and distribute rodent models. genOway S.A....
BioCentury | Mar 1, 2010
Company News

Cellectis, genOway deal

...The companies settled a dispute concerning Cellectis' 2009 termination of a 2001 deal that granted genOway...
...homologous recombination technology for cellular and animal model development. The deal will remain terminated, but genOway...
...Nov. 12, 2009. Last year, Cellectis ended its non-exclusive license deal with genOway alleging that genOway...
BioCentury | Nov 23, 2009
Company News

Cellectis, genOway functional genomics news

...Paris' Tribunal de Grande Instance dismissed genOway's lawsuit that challenged Cellectis' termination of a 2001 deal...
...genOway, covering the use of homologous recombination for cellular and animal model development, alleging that genOway...
...BioCentury, Jan. 12). As a result of the dismissal, the deal will remain terminated and genOway...
BioCentury | Oct 26, 2009
Company News

genOway, Institute of Genetics and Molecular and Cellular Biology deal

...technology induces mutations in selected tissue at exact time points. Financial terms were not disclosed. genOway S.A....
Items per page:
1 - 10 of 40
BioCentury | Nov 10, 2016
Strategy

Editing the claims

...exclusive licensing option to Servier to develop and commercialize six Cellectis cancer products; and granted genOway S.A....
...NASDAQ:CLLS), Paris, France CRISPR Therapeutics AG (NASDAQ:CRSP), Basel, Switzerland Editas Medicine Inc. (NASDAQ:EDIT), Cambridge, Mass. genOway S.A....
BioCentury | Feb 10, 2014
Company News

Cellectis, genOway deal

...Cellectis granted genOway an exclusive sublicense to Cellectis' homologous recombination technology for research applications in genetically...
...to Cellectis' homologous recombination technology for research applications in genetically modified rodents. Under the deal, genOway...
...Paris, France). Cellectis has exclusive rights to the institute's technology. Cellectis S.A. (Euronext:ALCLS), Paris, France genOway S.A....
BioCentury | Mar 26, 2012
Company News

genOway, StemCells deal

...dual expression of a protein of interest and a selectable marker. Details were not disclosed. genOway S.A....
BioCentury | Jul 18, 2011
Company News

bluebird bio, genOway deal

...bluebird granted genOway exclusive, worldwide rights to its RMCE technology for use in genetically modified rodents...
...sequence at a specific locus. Terms were not disclosed. bluebird bio Inc. , Cambridge, Mass. genOway S.A....
BioCentury | Mar 21, 2011
Company News

Genfit, OSEO diagnostic news

...cardiovascular disease. Genfit will lead the consortium of the program, which includes functional genomics company genOway S.A....
BioCentury | Jun 21, 2010
Company News

genOway deal

...to develop genetically modified animal models for testing pharmaceutical compounds. Further details were not disclosed. genOway S.A....
BioCentury | May 24, 2010
Company News

genOway, Griffith University deal

...to establish germline transmission in rats. Both partners are responsible for their respective R&D costs. genOway...
...receive an exclusive, worldwide license to use the technology to create and distribute rodent models. genOway S.A....
BioCentury | Mar 1, 2010
Company News

Cellectis, genOway deal

...The companies settled a dispute concerning Cellectis' 2009 termination of a 2001 deal that granted genOway...
...homologous recombination technology for cellular and animal model development. The deal will remain terminated, but genOway...
...Nov. 12, 2009. Last year, Cellectis ended its non-exclusive license deal with genOway alleging that genOway...
BioCentury | Nov 23, 2009
Company News

Cellectis, genOway functional genomics news

...Paris' Tribunal de Grande Instance dismissed genOway's lawsuit that challenged Cellectis' termination of a 2001 deal...
...genOway, covering the use of homologous recombination for cellular and animal model development, alleging that genOway...
...BioCentury, Jan. 12). As a result of the dismissal, the deal will remain terminated and genOway...
BioCentury | Oct 26, 2009
Company News

genOway, Institute of Genetics and Molecular and Cellular Biology deal

...technology induces mutations in selected tissue at exact time points. Financial terms were not disclosed. genOway S.A....
Items per page:
1 - 10 of 40